Skip to main content

Colovesical & Small Bowel Fistulas

Enterovesical fistulas are abnormal communications between bowel and bladder. The two clinically dominant subtypes are colovesical fistula (CVF) — usually a sigmoid-to-bladder communication driven by diverticulitis — and small-bowel (ileovesical) fistula, which is overwhelmingly a complication of Crohn's ileocolitis. The two share a characteristic symptom cluster (pneumaturia + fecaluria + recurrent polymicrobial UTI) but differ enough in etiology, demographics, and management that they are best treated as separate entities.

For operative selection, see the Fistula Repair (All Patients) database.

See also: The Bladder, Bowel Anatomy, Fistulas landing page.

Part 1 — Colovesical Fistula​

Definition​

A colovesical fistula is an abnormal communication between the colon (most commonly the sigmoid) and the urinary bladder. It is the most common type of uroenteric fistula and the most common fistula complicating diverticular disease, accounting for 65% of all diverticulitis-related fistulae.[1]

Epidemiology​

  • Fistulae occur in approximately 5% of patients with acute diverticulitis on initial presentation and account for 17–27% of surgically treated cases of diverticular disease.[1]
  • Strong male predominance (~2–6:1 male:female), attributed to the protective interposition of the uterus between the sigmoid colon and bladder in women. In women, CVF is more common after hysterectomy.[2][3]
  • Mean age at presentation 55–60 years.[3][4]

Etiology​

CauseFrequency
Diverticular disease41–75% — most common[4][5]
Colorectal cancer~16% — malignancy was missed preoperatively in half of cancer-related cases in one series, underscoring the need for colonoscopy in every patient[4][5]
Crohn's disease~17%[5]
Bladder cancer~8%[4]
Radiation therapyPelvic radiotherapy for cervical, rectal, or prostate cancer[5]
OtherAppendicitis, foreign body, trauma, post-surgical

Pathogenesis​

  • Diverticulitis: recurrent or complicated diverticulitis → pericolic abscess → erosion through the bladder wall (typically dome or posterior wall in direct contact with the sigmoid)
  • Malignancy: direct tumor invasion across intervening planes
  • Crohn's disease: transmural inflammation → penetrating disease → fistulization to adjacent organs[6][7]

Clinical Presentation​

The classic triad is pneumaturia, fecaluria, and recurrent UTI. Symptoms are predominantly urologic.[2][3][4]

SymptomFrequency
Pneumaturia (also exclude instrumentation and gas-forming UTI)71–95%[2][3][4]
Fecaluria (pathognomonic)36–82%[2][3]
Recurrent UTI, often polymicrobial enteric78–100%[2][8]
Dysuria / frequency45–100%[2][4]
Hematuria22–63%[4][9]
Orchitis (retrograde infection)~10%[4]
Abdominal painVariable

The diagnosis is primarily clinical — in 50 of 51 patients in one series the fistula was identified on the basis of history and urine culture alone.[5]

Evaluation​

No single test is perfectly sensitive; a multimodal approach is recommended.[2][4][8]

Poppy seed test — selected diagnostic adjunct​

One original 17-patient study used 250 g of poppy seeds with urine inspection for 48 hours. Published protocols vary; this is a historical study method, not a standardized ingestion prescription. Small studies report high sensitivity, but the test does not define anatomy, cause or malignancy:[10][11]

  • 94.6–100% sensitivity across series[2][11]
  • Significantly more sensitive than CT (70%, p = 0.03) in a prospective comparison[11]
  • Useful when conventional imaging is nondiagnostic[10]

A 2025 multicenter study proposed a structured diagnostic algorithm centered on early recognition with targeted use of colonoscopy, cystoscopy, CT, and the poppy seed test.[8]

CT abdomen / pelvis​

Most commonly used modality, sensitivity 61–90%.[2][4] Key findings: intravesical air (also consider recent instrumentation and gas-forming infection), bladder-wall thickening adjacent to a thickened colonic segment, pericolic inflammation, and occasional direct visualization of the tract.[4]

Diagnostic test sensitivities​

These are historical series-specific estimates from heterogeneous populations and techniques, not a validated ranking of tests. CT defines anatomy and complications; endoscopy primarily evaluates etiology.

TestSensitivityRole
Poppy seed test94.6–100%Confirms fistula presence[10][11]
CT abdomen / pelvis61–90%Identifies etiology, anatomy, complications[2][4]
MRI abdomen~60%Alternative to CT; soft-tissue detail[2]
Barium enema / Bourne test20–50% (up to 90% with Bourne)Demonstrates the tract[3][12]
Retrograde colonic enema35.7%Demonstrates the tract[2]
Cystogram11–16.7%Low sensitivity; rarely diagnostic[2][3]
Cystoscopy10.2%Rules out bladder malignancy[2]
Colonoscopy8.5%Rules out colonic malignancy (essential)[2]

Evaluate the colon for malignancy after acute inflammation settles, unless a sufficiently recent adequate examination already establishes the diagnosis. Cystoscopy is particularly useful when imaging, hematuria or risk factors raise concern for a bladder lesion; it is not necessarily required solely to visualize every otherwise well-characterized diverticular fistula.[2][4]

Management​

Surgery is recommended for most patients with CVF — spontaneous closure is rare.[1][13]

One-stage resection with primary anastomosis​

Commonly performed in suitable patients after infection control; operative staging depends on physiologic stability, contamination, tissue quality and comorbidity.[5][13]

  • Resection of the diseased sigmoid, primary colorectal anastomosis (with or without protective loop ileostomy), and management of the bladder defect
  • In a systematic review of 1,061 patients, one-stage resection with primary anastomosis was the most common procedure: Clavien-Dindo ≥ 3 7.4%, 30-day mortality 1.5%, recurrence 0.5%[13]
  • 0% mortality, 8.2% morbidity, no recurrences at median 68-month follow-up in a 49-patient series[2]

Bladder management​

Formal bladder repair is often unnecessary. In a 74-patient series of benign EVF, the bladder side was managed by Foley catheter alone in 68% of cases, with surgical repair in only 32%; all bladder defects healed within 1 week. A negative intraoperative bladder leak test supports conservative management.[13][14]

Multi-stage procedures​

Reserved for complicated presentations.[3][5]

  • Two-stage: Hartmann's resection with end colostomy → colostomy reversal — for significant abscess, obstruction, or poor patient condition
  • Three-stage: diverting colostomy → resection → reversal — for emergent presentations
  • Diversion alone often does not close the fistula; persistent urinary infection occurred in one small series. It may nevertheless be appropriate for selected patients needing palliation or staged source control.[5]

Minimally invasive approaches​

  • Laparoscopic and robotic approaches are increasingly considered the first-choice approach.[13][15]
  • 2016–2022 national database analysis: minimally invasive surgery had significantly shorter LOS (6.9 vs 7.3 days, p < 0.05).[16]
  • Robotic surgery for fistulizing diverticulitis: conversion rate 1.1% (1/89) with 1% fistula recurrence at median 16.5-month follow-up.[15]

Conservative / medical management​

Consider for selected patients with minimal symptoms, prohibitive operative risk or a preference to avoid surgery, with explicit follow-up for infection, obstruction and malignancy. Treat symptomatic infection and tailor any suppressive strategy; a small noncomparative series does not establish antibiotics as universally preferable to diversion.[5]

Part 2 — Small-Bowel (Ileovesical) Fistula​

Definition​

A small-bowel enterovesical fistula is an abnormal communication between the small intestine — most commonly the terminal ileum — and the urinary bladder, termed an ileovesical fistula. Etiology, demographics, and management differ enough from CVF to warrant a separate framework.[9][17]

Epidemiology​

  • Crohn's disease is the dominant cause; EVF occurs in approximately 2% of Crohn's patients.[9]
  • Among Crohn's-related EVF, 78–88% originate from the ileum (ileovesical), with the remainder from the sigmoid (sigmoidovesical or ileosigmoidovesical).[9][17]
  • Mean age at diagnosis is markedly younger than CVF — approximately 27 years in Crohn's-related series.[9]
  • Symptom-to-diagnosis interval ranges from 6 months to 15 years.[9]

Etiology​

  • Crohn's disease — dominant cause; the penetrating phenotype of ileocolitis drives transmural inflammation and fistulization to adjacent structures.[7][18]
  • Diverticulitis — uncommon (typically produces colovesical rather than ileovesical fistulae)
  • Colorectal / small-bowel malignancy — rare
  • Radiation therapy — delayed pelvic-radiation complication
  • Post-surgical — anastomotic leak or inadvertent bowel injury

Clinical Presentation​

Presentation is similar to CVF but typically arises in the context of active Crohn's disease with other complications.[9][19]

SymptomFrequency
Pneumaturia (strongest indicator)88%[9]
UTI symptoms88%[9]
Hematuria63%[9]
Fecaluria38%[9]
Concomitant enteroenteral fistulae37.5% in Crohn's EVF — supports thorough small-bowel evaluation[9]

A Crohn's disease exacerbation coincided with the appearance of the fistula in all 29 patients in one series.[19]

Evaluation​

The diagnostic approach mirrors CVF, with notable differences:[6][9]

  • CT abdomen / pelvis — primary imaging modality; identifies intravesical air, bowel-wall thickening, and complications (abscess, stricture)
  • Cystoscopy — more useful in EVF than CVF; suggestive of the diagnosis in 18 of 20 patients (90%) in one Crohn's series and useful for ureteral evaluation[19]
  • Barium / gastrografin small-bowel studies — identify the fistulous tract and detect concomitant enteroenteral fistulae[9]
  • Colonoscopy — assesses Crohn's activity and excludes malignancy
  • MR enterography — increasingly used for penetrating Crohn's complications

Management​

Management differs significantly from CVF because medical therapy plays a much larger role, particularly in Crohn's disease.

Medical therapy — an option for selected Crohn’s-related fistulas​

Coordinate gastroenterology and colorectal/urologic assessment. Medical therapy may be reasonable for selected Crohn’s-related fistulas without uncontrolled infection, obstruction or another operative indication; drain abscesses before immunosuppression.[7][18]

  • Anti-TNF therapy (infliximab, adalimumab) ± immunomodulators is the cornerstone
  • A small systematic-review subgroup included 14 enterovesical fistulas treated with anti-TNF: 8 complete, 5 partial and 1 no response. Low-quality heterogeneous evidence limits generalizability.[20]
  • A retrospective study of 93 internal Crohn’s fistulas included only 16 enterovesical fistulas. Its cumulative surgery estimates (18%, 27%, 37%, 47% at 1–5 years) apply to the mixed cohort, not an EVF-specific prognosis.[18]
  • Lower CDAI and a shorter interval between fistula diagnosis and starting anti-TNF therapy were independently associated with lower risk of needing surgery.[18]
  • For patients with isolated ileovesical fistula (without other Crohn's complications), medical therapy is the first choice; 35.1% achieved long-term remission over a mean of 4.7 years.[17]
  • Recurrent symptomatic UTI, especially with pyelonephritis (relative indication per ACG)[7]
  • Concurrent Crohn's complications — small-bowel obstruction, abscess, enterocutaneous fistula, or persistent ureteral obstruction (significant risk factor for surgery, p = 0.001)[17]
  • Sigmoid-originated EVF — more likely to require surgery than uncomplicated ileovesical fistula (p = 0.019)[17]
  • Failure of optimized biologic therapy
  • The mere presence of a fistula does not mandate surgery, especially in the absence of malabsorption, intractable diarrhea, or recurrent infection.[18]

Surgical management​

When surgery is required, the principles are:[9][14][18][19]

  • Resection of the diseased bowel (typically ileocecal resection) with primary anastomosis
  • Bladder management:
    • Foley catheter alone was sufficient in 68% of cases in a large series of benign EVF — bladder defects healed within 1 week[14]
    • Primary two-layer closure with absorbable suture ± omental interposition — when there is an overt bladder defect[9][19]
    • No bladder leaks occurred with either approach across multiple series[9][14][19]
  • Noninflamed bowel (e.g., sigmoid secondarily involved by an ileal fistula) can be primarily repaired rather than resected.[18][21]
  • Diversion (ileostomy or colostomy) may be required; reversal timing depends on healing, disease control and fitness rather than a fixed six-month promise.[9]
  • Postoperative outcomes in Crohn's series: 0% mortality, mean LOS 9 days, no recurrences at mean 39-month follow-up.[9]

Colovesical vs. Ileovesical Fistula — Key Differences​

FeatureColovesical FistulaSmall-Bowel (Ileovesical) Fistula
Most common causeDiverticular disease (41–75%)Crohn's disease (~80%)
Age at presentation55–60 years~27 years (Crohn's)
Sex predominanceMale (2–6:1)Equal or slight male predominance
Role of medical therapyLimited; surgery is standardFirst-line for uncomplicated Crohn's
Anti-TNF response rateNot applicable to diverticular CVF8/14 complete responses in one small review subgroup
Need for surgeryCommon in symptomatic diverticular CVFDepends on infection, obstruction, associated disease and medical response
Bladder repair neededOften not (Foley alone in 68%)Often not (Foley alone in 68%)
Recurrence after surgery0.5–1%Low (data limited)

Outcomes​

  • Colovesical fistula: surgical outcomes are excellent — Clavien-Dindo ≥ 3 7.4%, 30-day mortality 1.5%, recurrence 0.5%; minimally invasive approaches now produce shorter LOS and a 1% recurrence rate at median 16.5-month follow-up.[13][16]
  • Small-bowel EVF in Crohn's disease: medical therapy can achieve durable remission in 35–57% of patients; when surgery is required, outcomes are excellent with no mortality and no recurrences in most series. The dominant prognostic factor is the presence of concurrent Crohn's complications, which significantly increases the likelihood of needing surgery.[9][17]

See Also​

References​

1. Brown RF, Lopez K, Smith CB, Charles A. "Diverticulitis." JAMA. 2025. doi:10.1001/jama.2025.10234

2. Melchior S, Cudovic D, Jones J, et al. "Diagnosis and Surgical Management of Colovesical Fistulas Due to Sigmoid Diverticulitis." J Urol. 2009;182(3):978–982. doi:10.1016/j.juro.2009.05.022

3. El-Haddad HM, Kassem MI, Sabry AA, Abouelfotouh A. "Surgical Protocol and Outcome for Sigmoidovesical Fistula Secondary to Diverticular Disease of the Left Colon: A Retrospective Cohort Study." Int J Surg. 2018;56:115–123. doi:10.1016/j.ijsu.2018.05.742

4. Najjar SF, Jamal MK, Savas JF, Miller TA. "The Spectrum of Colovesical Fistula and Diagnostic Paradigm." Am J Surg. 2004;188(5):617–621. doi:10.1016/j.amjsurg.2004.08.016

5. Moss RL, Ryan JA. "Management of Enterovesical Fistulas." Am J Surg. 1990;159(5):514–517. doi:10.1016/s0002-9610(05)81259-0

6. Gill HS. "Diagnosis and Surgical Management of Uroenteric Fistula." Surg Clin North Am. 2016;96(3):583–592. doi:10.1016/j.suc.2016.02.012

7. Lichtenstein GR, Loftus EV, Afzali A, et al. "ACG Clinical Guideline: Management of Crohn's Disease in Adults." Am J Gastroenterol. 2025;120(6):1225–1264. doi:10.14309/ajg.0000000000003465

8. Zimniak L, Ritz JP, Wullstein C, et al. "The Diagnostic Journey in Fistulizing Sigmoid Diverticulitis: A Multicenter Retrospective Study and Proposal for a Structured Workup." Dig Dis. 2025:1–9. doi:10.1159/000549576

9. Gruner JS, Sehon JK, Johnson LW. "Diagnosis and Management of Enterovesical Fistulas in Patients With Crohn's Disease." Am Surg. 2002;68(8):714–719.

10. Schwaibold H, Popiel C, Geist E, Hartung R. "Oral Intake of Poppy Seed: A Reliable and Simple Method for Diagnosing Vesico-Enteric Fistula." J Urol. 2001;166(2):530–531. doi:10.1016/s0022-5347(05)65976-9

11. Kwon EO, Armenakas NA, Scharf SC, Panagopoulos G, Fracchia JA. "The Poppy Seed Test for Colovesical Fistula: Big Bang, Little Bucks!" J Urol. 2008;179(4):1425–1427. doi:10.1016/j.juro.2007.11.085

12. Amendola MA, Agha FP, Dent TL, Amendola BE, Shirazi KK. "Detection of Occult Colovesical Fistula by the Bourne Test." AJR Am J Roentgenol. 1984;142(4):715–718. doi:10.2214/ajr.142.4.715

13. Froiio C, Bernardi D, Asti E, et al. "Burden of Colovesical Fistula and Changing Treatment Pathways: A Systematic Literature Review." Surg Laparosc Endosc Percutan Tech. 2022;32(5):577–585. doi:10.1097/SLE.0000000000001099

14. Ferguson GG, Lee EW, Hunt SR, Ridley CH, Brandes SB. "Management of the Bladder During Surgical Treatment of Enterovesical Fistulas From Benign Bowel Disease." J Am Coll Surg. 2008;207(4):569–572. doi:10.1016/j.jamcollsurg.2008.05.006

15. Sassun R, Sileo A, Ng JC, et al. "Diverticular Disease Complicated by Colovesical and Colovaginal Fistulas: Not So Complex Robotically." Surg Endosc. 2025;39(6):3941–3946. doi:10.1007/s00464-025-11754-w

16. Volkert A, Nigam A, Stover D, et al. "Comparison of Open Versus Minimally Invasive Repair of Colovesical Fistula: A Case Report and Propensity-Matched National Database Analysis." J Clin Med. 2025;14(17):6065. doi:10.3390/jcm14176065

17. Zhang W, Zhu W, Li Y, et al. "The Respective Role of Medical and Surgical Therapy for Enterovesical Fistula in Crohn's Disease." J Clin Gastroenterol. 2014;48(8):708–711. doi:10.1097/MCG.0000000000000040

18. Lightner AL, Vogel JD, Carmichael JC, et al. "The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Crohn's Disease." Dis Colon Rectum. 2020;63(8):1028–1052. doi:10.1097/DCR.0000000000001716

19. Schraut WH, Block GE. "Enterovesical Fistula Complicating Crohn's Ileocolitis." Am J Gastroenterol. 1984;79(3):186–190.

20. Kaimakliotis P, Simillis C, Harbord M, et al. "A Systematic Review Assessing Medical Treatment for Rectovaginal and Enterovesical Fistulae in Crohn's Disease." J Clin Gastroenterol. 2016;50(9):714–721. doi:10.1097/MCG.0000000000000607

21. Schraut WH, Chapman C, Abraham VS. "Operative Treatment of Crohn's Ileocolitis Complicated by Ileosigmoid and Ileovesical Fistulae." Ann Surg. 1988;207(1):48–51. doi:10.1097/00000658-198801000-00010